Objective To investigate the effect of maple syrup on fatigue resistance in mice. Methods Totally forty Kunming mice were divided randomly into normal control group, low-dose maple syrup group (1.25g/kg), medium-dose maple syrup group (2.50g/kg), and high-dose maple syrup group (5.00g/kg). Mice were continuously given water and maple syrup through mouth for 30 days. Various groups swam for 10min. The contents of blood lactic acid were measured at swimming 0min, 10min and resting 30min. The contents of hemoglobin, blood lactic acid, serum urea nitrogen, muscle glycogen, and liver glycogen of various group mice were detected after resting 30min. Results The content of serum urea nitrogen of three maple syrup groups was less than that in normal control group (P

Objective To investigate the cytotoxicity on normal cell lines of cerium nitrate, the inhibitory effect on tumor cell lines and the effect on cell cycle in vitro. Methods The cytotoxicity of cerium nitrate on FL, L929 and inhibition rate on Hela, SGC-7901, B16, Lewis, K562, and H_(22) in vitro were detected with the method of MTT. The effect of cerium nitrate on cell cycle of SGC-7901 was studied by one-fluorescence dying method on flow cytometer. Results Cerium nitrate did not show the toxic activities on FL and L929 cell lines when the dose of cerium nitrate was it could noticeably inhibit the growth and proliferation of tumor cells nitrate inhibited the growth and proliferation of tumer cells including HeLa, SGC-7901, B16 and K562; cerium nitrate had a noticeably inhibitory effect on the growth and proliferation of H_(22) cell lines in vitro on Conclusion Cerium nitrate has the property of low toxicity and high selectivity on normal cells, but it can inhibit growth and proliferation of many kinds of tumor cell lines by adjusting cell cycle.

OBJECTIVE To investigate the treatment plan for az treonam-resistant metallo- β-lactamase（MBL）-producing Enterobacteriaceae infection in pediatric solid organ transplant recipients. METHODS The clinical data of aztreonam-resistant MBL-producing Klebsiella pneumoniae caused intra-abdominal infection of an infant after liver transplantation were retrospectively analyzed. Abdominal infection occurred after operation. The pathogenic bacterium was MBL-producing K. pneumoniae . The drug sensitivity results showed that the infant was resistant to aztreonam. Based on the results of sensitivity test ，polymyxin B combined with tigecycline were selected as initial regimen. The treatment effect was poor ，with recurrent disease and shock spots. The clinical pharmacist assisted the clinician to formulate treatment regimen of ceftazidime avibactam 0.5 g，q8 h combined with aztreonam 0.18 g，q6 h. Relevant domestic and foreign literature were reviewed ，and the treatment plan of MBL-producing Enterobacteriaceae infection after solid organ transplantation was summarized. RESULTS & CONCLUSIONS The infant was finally cured and discharged with ceftazidime avibatan combined and aztreonam. Several foreign literature reported that ceftazidime avibactam combined with aztreonam could effectively treat the infection caused by aztreonam-resistant MBL-producing Enterobacteriaceae infection in patients with organ transplantation. It is expected to be an effective treatment for aztreonam-resistant MBL-producing Enterobacteriaceae infection in pediatric solid organ transplant recipients.

ABSTRACT: Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations. The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), published in 2021, introduces major changes that advance the role of molecular diagnostics in meningiomas. To follow the revision of WHO CNS5, this expert consensus statement was formed jointly by the Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association together with neuropathologists and evidence-based experts. The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients. REGISTRATION Practice guideline REgistration for transPAREncy (PREPARE), IPGRP-2022CN234.
Humans ; Meningioma/pathology* ; Consensus ; Neurosurgical Procedures ; Meningeal Neoplasms/pathology*